NRX Pharmaceuticals, Inc. (NRXP) Form 424B5 — Jun 2, 2026
NRx Pharmaceuticals, Inc. (NRXP) filed a prospectus supplement for a firm commitment underwritten offering of common stock, with BTIG and Lucid Capital Markets acting as underwriters. The filing is dated June 2, 2026, but notably omits the specific offering price, number of shares offered, and gross proceeds, indicating the deal terms are not yet finalized or were redacted in this version. The company disclosed a negative net tangible book value of approximately $(16.5) million, or $(0.46) per share, as of March 31, 2026.
Key figures
- Last Sale Price
- 4.62
- Shares Outstanding
- 36228992
- Gross Proceeds
- Not stated (blank in filing)
- Offering Price
- Not stated (blank in filing)
- Shares Offered
- Not stated (blank in filing)
- Options Outstanding
- 687490
- Warrants Outstanding
- 9359710
- Underwriting Discount
- Not stated (blank in filing)
- Restricted Stock Awards
- 32895
Price after filing
Close on the filing date to close N calendar days later (from $4.62). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.